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Abstract   
Introduction: In Kenya, which ranks thirteenth of 27 high tuberculosis burden countries, diagnosis is based on Ziehl-Neelsen staining alone 
and patients are treated without information on sensitivity patterns. This study aimed to determine resistance patterns of Mycobacterium 
tuberculosis isolated from pulmonary samples. 
Methodology: Pulmonary tuberculosis patients in Nairobi were randomly sampled after informed consent and recruited into the study using a 
structured questionnaire. Specimens were cultured in liquid and solid media, and drug susceptibility tests were performed for first-line drugs 
including (isoniazid, rifampin, streptomycin, ethambutol and pyrazinamide).  
Results: Eighty-six (30%) of 286 isolates were resistant to at least one of five antibiotics tested. Thirty-seven (30.2%) isolates were resistant 
to isoniazid; 15 (11.6%) to streptomycin; 13 (4.5%) to ethambutol; four (1.4%) to rifampin ; and 30 (10.4%) to pyrazinamide. Double 
resistance was seen as follows: four (1.4%) isolates were resistant to both isoniazid and pyrazinamide; four (1.4%) to streptomycin and 
isoniazid; and one (0.3%) to rifampin and streptomycin. Two isolates (0.7%) were multidrug resistant, and one was triple resistant with an 
additional resistance to ethambutol. Results also showed 88.7% of patients were below the age of 40 years, while 26.3% were HIV positive. 
The majority of the patients (66.5%) were unemployed or self-employed in small businesses, with 79.4% earning less than 100 USD per 
month. 
Conclusion: The high resistance observed in isoniazid, which is a first-line drug, could result in an increase in multidrug resistance unless 
control programs are strengthened. Poverty should be addressed to reduce infection rates. 
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Introduction 
Tuberculosis (TB) has been reported to be 
responsible for 1.7 million deaths annually [1]; 
however, tuberculosis programs face tremendous 
challenges in reducing multidrug-resistant 
tuberculosis (MDR-TB). Since 1994, only 59% of all 
countries globally have been able to collect high-
quality representative data on drug resistance [1]. 
Kenya is ranked thirteenth among the 27 high-burden 
TB countries in the world and has the fifth highest 
burden in Africa [1]. The Kenya National Division of 
Leprosy, TB and Lung disease (DLTLD) began to 
implement World Health Organization (WHO) direct 
observation therapy (DOT) for tuberculosis in 1993 
and reported100% coverage by 1996. In 2005 the 
DOT case detection rate reached the WHO target of 
70% and rose to 72% in 2007 using the Becton and 
Dickson BACTEC MGIT 960 (Loveton Circle, 
Sparks, USA) technique on the first-line drugs used 
for treatment of TB [2]. The DOT treatment success 
rate met WHO’s target of 85% in 2007.  However, 
the WHO Global TB report for 2009 [3] estimated 
that Kenya had approximately 132,000 new TB cases 
and an estimated 74,000 people died. There are 2,000 
treatment facilities and 900 TB diagnosis facilities 
throughout the country but they do not cater to drug-
resistant TB because laboratory diagnosis is mainly 
based on Ziehl-Neelsen staining (ZN) without culture 
and sensitivity tests. MDR-TB, which is defined as 
TB resistant to at least both isoniazid and rifampin, 
has been reported since the 1980s in Kenya [4]. 
According to USAID, it is estimated that there may 
have been as many as 2,000 MDR-TB cases in Kenya 
in 2007, although only 4.1% of these individuals  
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were diagnosed and notified [5]. MDR-TB patients 
are either not receiving treatment or have been 
allowed out of hospital because the government does 
not have money to treat them. Of the 300 patients 
diagnosed with MDR-TB in 2009, only 44 were 
receiving treatment while the remaining 256 were not 
in any structured treatment [3]. According to the 
WHO, an MDR patient infects 10-15 people every 
year [5]. Treatment for MDR-TB lasts for 18 months 
but can extend to two years or more because it is 
difficult to cure and drugs used for treatment are less 
potent, more toxic and 50-200 times more expensive 
than first-line drugs. If not properly treated it can 
result in complications that may require surgical 
interventions increasing period of hospitalization and 
raising the cost of treatment even higher.  
The WHO estimates that globally 4.5 million 
people are co-infected with HIV and TB [6]. In 
Kenya, about 20% of the 1.2 million HIV-positive 
individuals also have TB. Studies show that TB 
patients co-infected with HIV are at a higher risk of 
having MDR-TB compared to patients without HIV 
infection [1]. Little information is available in Kenya 
on the resistance patterns of M. tuberculosis; 
therefore, this study was undertaken to determine M. 
tuberculosis resistance patterns against the first-line 
drugs used for treatment in patients diagnosed with 
pulmonary tuberculosis. 
  
Methodology  
Selection of patient population 
A total of five hospitals and TB clinics from 
various locations in and around Nairobi, Kenya, were 
randomly sampled. These included the Kangemi, 
Riruta, and Mbagathi TB clinics as well as Kiambu 
District Hospital and Nazareth Hospital (Table 1). 
 The study was conducted between April and 
December 2010 when 356 pulmonary adult TB 
patients (18 years of age and older), who consented to 
enroll, were systematically sampled on the basis of  
 
 
 
being newly clinically diagnosed cases. Out of these 
286 173 males (60.3%) and 113 (39.7%) females 
were sputum culture positive. 
 
 Methodology 
Two early morning sputa and a spot sample were 
collected in sterile screw-capped bottles. They were 
decontaminated with NaOH solution (40g/l4% w/v) 
combined with 2.9% sodium citrate solution and N-
acetyl-L-cystein (NALC) powder. Sterile phosphate 
buffer was added and the organisms concentrated by 
centrifugation at 3,000 rpm for 15 minutes.  The 
supernatant was decanted and the sediment 
suspended with phosphate buffer and inoculated in 
liquid MGIT media and incubated in BACTEC 960 
system (BD Diagnostic Systems, , Sparks, MD, USA) 
for a maximum of eight weeks until the culture 
flagged positive. The residue was also inoculated in 
Lowenstein Jensen (LJ) solid medium and incubated 
at 37
o
 C for a maximum of 12 weeks. The growth of 
M. tuberculosis thus obtained was used for sensitivity 
testing. Statistical analysis was performed by 
multiple logistic regression using SPSS version 17 
(IBM, Chicago, USA). 
 
Sensitivity testing of M. tuberculosis 
All positive tubes were tested for contamination 
before sensitivity tests using the standard method 
used in Kenya for drug sensitivity testing using the 
BACTEC MIGIT 960 liquid culture system (Becton- 
Dickson and Company, Sparks, MD, USA). 
 A total of five first-line drugs collectively 
referred to as SIRE (streptomycin [S] - 1.00µg/ml; 
isoniazid [INH] - 0.10 µg/ml; rifampin [Rif] - 1.00 
µg/ml; and ethambutol [E], 5.00 µg/ml) were tested 
for sensitivity along with pyrazinamide (PZA, 100.0 
µg/ml). A control tube was matched with all the 
isolates tested. An external control of Rv 37 was also 
set in all culturing and sensitivity testing processes.  
 
 
Hospital Constituency Population No. of filter 
clinics 
TB patient 
population (2010) 
No. of patients 
sampled 
Kangemi Westlands 247,102 10 70 35 
Riruta Dagoretti 329,577 6 130 77 
Mbagathi Langata 355,188 20 1390 118 
Kiambu Kiambaa 253,751 12 125 99 
Nazareth Githunguri 147,763 10 28 27 
Table 1. Summary of the clinics sampled and patient population 
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Each patient was required to complete a structured 
questionnaire upon giving informed consent. 
 
Ethical approval 
The research proposal was approved and 
ethically cleared by the national ethical research 
committee (ERC) at the Kenya Medical Research 
Institute (KEMRI). Permission was also obtained 
from Health Department of Nairobi city council to 
sample city council clinics and from the Medical 
Officer of Health (MOH) at the Kiambu District 
Hospital. Each patient who consented to enroll was 
required to complete an informed consent form.  
 
Results     
A total of 286 sensitivity tests were performed 
from pulmonary tuberculosis patients of whom 173 
(60.4 %) were male while 113 (39.5%) were female. 
The majority of the patients (88.7%) were below the 
age of 40 years while the rest (11.2%) were above the 
age of 40 years with only three patients (1%) above 
the age of 60 years. Among the pulmonary 
tuberculosis patients 26.3% were HIV positive. The 
majority of the patients were either unemployed or 
self-employed in small businesses (66.5%) with only 
33.5% being in formal employment. The number of 
participants who were smokers or who consumed 
alcohol was also surveyed, and 29.7% of the patients 
were found to be smokers and 40% were alcohol 
consumers. 
A total of 86 (30.1%) strains showed resistance to 
at least one drug tested, while 200 (69.9%) were 
susceptible. Fifty-two (18.2%) males and 34 (11.9 %) 
females showed resistance to at least one drug. The  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
isolates showed different resistance patterns with 
monoresistance (resistance to at least one drug) in 70 
(24.4%) isolates, double resistance in 11 (3.8%) 
isolates, and triple resistance in on (0.3%) isolate. 
Monoresistance was recorded in all five drugs tested 
(Table 2). Isolates were resistant to the antibiotics 
tested as follows: 15 (5.2%) were resistant to S; 30 
(10.4 %) were resistant to PZA; 37 (12.9%) were 
resistant to INH; 13 (4.5%) were resistant to E; and 
four (1.4%) were resistant to Rif. Eleven (3.8%) 
antibiotics were double drug resistant, two (0.7%) of 
which were MDR. Four (1.4%) isolates were resistant 
to INH and PZA, 4 (1.4%) to S and INH and 1 
(0.3%) to Rif and S.  One MDR isolate was triple 
resistant with an additional resistance to E. 
 
Discussion 
Comparison of resistance on the basis of gender 
There was a significantly greater number of 
males diagnosed with pulmonary TB than females 
(60.4% and 39.5 % respectively; χ2 = 0.963; df = 1; P 
< 0.05). This differs with earlier studies in Kenya 
where more females were associated with drug 
resistance than males (OR = 2.3; 95%Cl 1.2-4.8; P = 
0.008) [7]. It compares with studies in Pakistan [8], 
however, where drug resistance was associated with 
70.9% males and 29.15% females, and also in 
Tanzania [9] where drug resistance was associated 
with68% males and 32% females.  Globally a 70% 
predominance of males over female patients was 
reported [10]. The World Health Organization 
reported that 67.2% of the global male population 
was diagnosed with TB as compared to the female 
population [6]. The greater number of males 
Drug resistance Patients N    (%) 
Resistance to any one drug 86   (30.1%) 
Mono resistance 
Isoniazid  
Ethambutol 
Streptomycin 
Pyrazinamide 
 
26   (12.9%) 
12   (4.5%) 
10   (5.2%) 
26   (12.9%) 
Double resistance 
Isoniazid  and rifampin 
Isoniazid and pyrazinamide 
Streptomycin and isoniazid 
Rifampin and streptomycin  
 
 2   (1.1%) 
 4   (4.6%) 
 4   (4.6%) 
 1   (1.2%) 
Triple resistance 
Isoniazid, rifampin, ethambutol 
 
 1   (1.2%) 
Table 2. Drug resistance patterns of Mycobacterium tuberculosis isolates from pulmonary tubercular 
patients in Nairobi 
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compared to females could be attributed to behavioral 
factors such as smoking, which is a predisposing 
factor to TB with more males being smokers than 
females. Alcohol consumption, malnutrition [11] and 
the delay in seeking medical treatment, especially by 
men [12], are other factors that have been associated 
with higher numbers of males than females with TB, 
with over 90% of the participants in the current study 
being male. 
  
Resistance patterns 
The overall resistance to all the drugs tested 
(30.1%) was much higher than that reported in earlier 
studies in Kenya, where 18.3% of isolates were 
resistant to at least one drug [7]. Resistance rates in 
Figure 1. Study profile 
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the present study were also higher than rates observed 
in studies in Tanzania where only 14 out of 280 
(5.83%) isolates were resistant to at least one drug 
[10], while in Ethiopia resistance rates ranged 
from14% to 27.4% [13,14]. In Korea total resistance 
was 18.7% [15], while in South Africa total 
resistance to the drugs tested was 7.3% [16]. The 
results of this study compare with those of studies 
conducted in Central Asia where resistance was 
30.5% [17]. All these studies were one-time studies 
performed in single facilities in the respective 
countries. Similarly, in the current investigation was 
also a one-time study performed in a single facility. 
Resistance to INH in this study was 12.9%, 
which was higher than results obtained in earlier 
studies in Kenya, where resistance to INH was 10.2% 
[18]. INH resistance in the present study was also 
much higher than that seen in Ethiopia, where one 
isolate was resistant to INH [19], and in Bangladesh 
and Sri Lanka at 5.4% [20] and   12.2% [21], 
respectively. It was, however, lower than that 
reported in Mozambique (14.9%) [22]. In 2008, the 
WHO reported a worldwide resistance rate to INH of 
5.9% [6]. According to the WHO, INH resistance 
rates higher than 10% can predict the development of 
MDR TB [23]. This high resistance may be caused by 
both its wide use in the treatment of TB as a first-line 
drug and/or poor compliance by patients. In this 
study, resistance to Rif was 1.3%, which is higher 
than that observed in earlier studies in Kenya where 
resistance was 0.3 % [18] and in an Ethiopian study 
where one isolate was resistant to Rif. This rate is 
also higher than reports from studies in Bangladesh 
where resistance was 0.5 % [21] and other studies in 
Ethiopia where resistance to Rif ranged from 0% to 
1.8% [10;15]. Rif has several adverse effects such as 
nausea, vomiting, rashes, hepatitis, GIT upset, flu-
like symptoms, fever and jaundice, which could 
result in patient non-adherence and hence may lead to 
the selection of resistant strains.  
Resistance to S in this study was 5.2%, which 
was higher than the resistance of 1.8% [18] reported 
in another study in Kenya, but lower than that 
reported in Ethiopia (26%) [19] and Sri Lanka 9.9% 
[22]. Resistance to E in this study was 4.5% which 
was higher than rates in Ethiopia 2.7% [19]. It was, 
however, lower than studies conducted in Sri Lanka 
where 14.5% resistance was reported [22]. 
Ethambutol enhances the effect of many drugs 
including beta lactams to different Mycobacteria 
species and can be used to develop a regimen for 
MDR TB [23]. 
In this study a high number of patients with TB 
showed INH resistance yet susceptibility to all other 
tested drugs. According to WHO guidelines for 
management of drug-resistant TB, drug-resistant 
patients can be classified into three groups: those 
releasing bacilli susceptible to all anti-TB drugs; 
those releasing bacilli resistant to INH but susceptible 
to Rif; and those releasing bacilli resistant to at least 
INH and Rif [24]. Most of the isolates in this study 
were resistant to INH but susceptible to Rif. It is 
therefore possible for these patients to recover fully if 
WHO guidelines for retreatment are followed under 
strict supervision to prevent them from developing 
MDR TB. However, the high rate of INH resistance 
is significant since it is a first-line drug which is used 
throughout the course of treatment. This indicates a 
high probability for developing MDR TB in the 
future since it has been observed that MDR often 
develops from initial INH monoresistant strains. INH 
is also the drug of choice for chemoprophylaxis of 
TB and is used in developed countries for treating 
latent TB. The high level of INH resistance among 
the study population also is an indicator that this drug 
will be completely useless for both these purposes in 
Kenya.  
In this study two patients had MDR-TB (2.3%) 
which is not unusual because in sub-Saharan African 
countries MDR TB prevalence is estimated to be 
6.3% [25]. 
 The results of this study indicate the need for 
strict enforcement of the DOTs method and better 
epidemiological surveillance of TB cases. Treatment 
with internationally approved regimens has resulted 
in high cure rates without emergence of resistance 
[8]. These regimens are effective in preventing the 
emergence of resistance because of inhibition of the 
development of spontaneous resistance due to 
mutation. 
  
Limitations of the study 
This study was conducted over a limited period 
of nine months and surveyed only sentinel sites 
mostly in high-population density areas of Nairobi 
and parts of its environs. Similar studies should be 
performed in other regions. 
 
Conclusion 
This study serves to inform that MDR may 
become an important phenotype in our health 
facilities unless TB control programs are 
strengthened and continuous systematic surveillance 
is adopted. There is urgent need to improve drug 
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susceptibility testing which is not routinely 
performed in public hospitals in Kenya. Furthermore, 
there is a need for patients to access rapid diagnosis 
and treatment with more effective drugs and also 
regimens shorter than the current two-year period for 
MDR-TB. Since two cases of XDR-TB have already 
been reported in Kenya, there needs to be a 
commensurate increase in human resources available 
for TB control in both public and private hospitals to 
avert a possible explosion of MDR TB. Since drug-
resistant TB is closely associated with HIV more 
research must be conducted to determine if there is an 
overlap between MDR-TB and the HIV epidemic. 
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